We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed. Abbott Laboratories (NYSE:ABT) is a ...

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Abbott Laboratories (NYSE ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

Abbott Laboratories, which makes the popular BinaxNow COVID-19 tests, expects significantly fewer sales of its COVID-19 tests in the fourth quarter compared with the rest of the year.

Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.